for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Alpine Immune Sciences Inc

ALPN.OQ

Latest Trade

4.35USD

Change

0.19(+4.57%)

Volume

9,210

Today's Range

4.15

 - 

4.35

52 Week Range

3.46

 - 

7.99

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.16
Open
4.25
Volume
9,210
3M AVG Volume
0.29
Today's High
4.35
Today's Low
4.15
52 Week High
7.99
52 Week Low
3.46
Shares Out (MIL)
18.59
Market Cap (MIL)
80.86
Forward P/E
-1.63
Dividend (Yield %)
--

Latest Developments

More

Alpine Immune Sciences Says ALPN-202 Submission For Clinical Trial Authorization Anticipated By Year End 2019

Alpine Launches HVAC, Plumbing And Electrical Services Platform Apex Service Partners With Acquisition Of Frank Gay Services

Alpine Immune Sciences- On May 20, Kite Pharma Provided Co Notice Of Termination Of License, Research Agreement, By And Between Ais Operating Co Inc

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Alpine Immune Sciences Inc

Alpine Immune Sciences, Inc., formerly Nivalis Therapeutics, Inc., is focused on developing a protein-based immunotherapies using Variant immunoglobulin domain (vlgD) platform technology. The vlgD platform is designed to interact with multiple targets, including many present in the immune synapse. The vlgDs are developed using a process known as directed evolution. The vlgD platform exploits both known and unknown interactions at immune synapse through a process called direct evolution for patients living with cancer, autominnue/inflammatory conditions and chronic infectious disease. It optimizes native immune system proteins for use as therapeutics. The Company also developed Transmembrane Immunomodulatory Protien (TIP) technology, based on the vIgD platform, to enhance engineered cellular therapies. TIP program is created to help companies focused on engineered cellular therapies.

Industry

Biotechnology & Drugs

Contact Info

201 Elliott Ave W Ste 230

+1.206.7884545

https://www.alpineimmunesciences.com/

Executive Leadership

Mitchell H. Gold

Executive Chairman of the Board, Chief Executive Officer

Stanford L. Peng

President and Head of Research and Development

Paul Rickey

Chief Financial Officer, Senior Vice President

Wayne R. Gombotz

Chief Technology Officer

Min Cui

Director

Key Stats

1.25 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-8.120

2017

-1.200

2018

-2.630

2019(E)

-2.665
Price To Earnings (TTM)
--
Price To Sales (TTM)
142.60
Price To Book (MRQ)
1.78
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
7.20
LT Debt To Equity (MRQ)
2.62
Return on Investment (TTM)
-74.69
Return on Equity (TTM)
-66.35

Latest News

BRIEF-Alpine Immune Sciences Appoints Chris Peetz To Its Board

* ALPINE IMMUNE SCIENCES APPOINTS LIFE SCIENCES EXECUTIVE CHRIS PEETZ TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Alpine Immune Sciences Provides Corporate Update And Reports Full Year 2017 Financial Results

* ALPINE IMMUNE SCIENCES PROVIDES CORPORATE UPDATE AND REPORTS FULL YEAR 2017 FINANCIAL RESULTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up